Development of novel therapeutic strategy against highly malignant tumors

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08394
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Experimental pathology
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: KITAGAWA Masanobu 東京医科歯科大学, 大学院医歯学総合研究科, 教授 (10177834)
• Co-Investigator(Renkei-kenkyūsha): YAMAMOTO Kouhei 東京医科歯科大学, 大学院医歯学総合研究科, 助教 (50451927) ; ABE Shinya 兵庫医科大学, 医学部, 助教 (70596725) ; HASEGAWA Maki 武田薬品 (00431958)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: アポトーシス誘導 / MCM2 / 悪性腫瘍の治療 / DNA損傷

Outline of Final Research Achievements

Some of malignant tumors are known to show highly　malignant　potential　and　worse　prognosis.　We　have　clarified　the function of MCM2　(minichromosome　maintenance 2) protein as the enhancer of the DNA-damage-induced apoptosis. In the present study, we introduced gp70 protein to tumor cells by the protein transduction experiment system and created the treatment experiments of highly malignant tumors in vitro and in vivo by using the interaction of MCM2 and gp70 to enhance apoptosis. The results showed the prominent enhancement of apoptosis to tumor cells by the treatment with gp70 and DNA-damage stimuli by doxorubicin. Not only leukemia cells but also soid tumors such as breast cancer and ovarian cancer revealed the successful reduction of tumor volume by the novel strategy of MCM2-targeted therapy.

Free Research Field

実験病理学